4.5 Article

The Open-Access European Prevention of Alzheimer?s Dementia (EPAD) MRI dataset and processing workflow

期刊

NEUROIMAGE-CLINICAL
卷 35, 期 -, 页码 -

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.nicl.2022.103106

关键词

Magnetic resonance imaging; EPAD; Image analysis pipeline; Quality control

资金

  1. EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD [115736]
  2. NIHR UCLH Biomedical Research Centre [539208]
  3. UK Dementia Research Institute at UCL [ARUK-NAS2016B-2, ARUK-PG2017-1946]
  4. UCLH NIHR Biomedical Research Centre [2020T049]
  5. Wellcome Trust [16 CVD 05]
  6. Alzheimer's Research UK [RYC-2013-13054]
  7. UK Dementia Research Institute - DRI Ltd.
  8. UK Medical Research Council
  9. Alzheimer's Society
  10. A.P.R.A. -Association Suisse pour la Recherche sur la Maladie d'Alzheimer, Gene`ve
  11. Ivan Pictet, Geneve
  12. Fondazione Agusta, Lugano
  13. Fondazione Agusta, Lugano
  14. Fondation Chmielewski, Geneve
  15. Swiss National Science Foundation
  16. VELUX Foundation
  17. Dutch Heart Foundation
  18. Eurostars-2 joint program
  19. European Union
  20. EU Joint Program for Neurodegenerative Disease Research
  21. UK Dementia Research Institute Ltd. - UK MRC
  22. UK Dementia Research Institute Ltd. - ARUK
  23. UK Dementia Research Institute Ltd. - Alzheimer Society
  24. Fondation Leducq
  25. Ramon y Cajal fellowship

向作者/读者索取更多资源

The European Prevention of Alzheimer Dementia (EPAD) study aims to characterize the early stages of Alzheimer's Disease using MRI data. This study presents a pipeline for curating, preprocessing, quality control, and computing image-derived phenotypes from the EPAD MRI dataset. The pipeline ensures standardized preprocessing and utilizes visual and quantitative assessments to evaluate image quality. The results demonstrate the potential of the dataset for future clinical analyses by showing associations with aging and dementia biomarkers.
The European Prevention of Alzheimer Dementia (EPAD) is a multi-center study that aims to characterize the preclinical and prodromal stages of Alzheimer's Disease. The EPAD imaging dataset includes core (3D T1w, 3D FLAIR) and advanced (ASL, diffusion MRI, and resting-state fMRI) MRI sequences. Here, we give an overview of the semi-automatic multimodal and multisite pipeline that we developed to curate, preprocess, quality control (QC), and compute image-derived phenotypes (IDPs) from the EPAD MRI dataset. This pipeline harmonizes DICOM data structure across sites and performs standardized MRI pre-processing steps. A semi-automated MRI QC procedure was implemented to visualize and flag MRI images next to site-specific distributions of QC features - i.e. metrics that represent image quality. The value of each of these QC features was evaluated through comparison with visual assessment and step-wise parameter selection based on logistic regression. IDPs were computed from 5 different MRI modalities and their sanity and potential clinical relevance were ascertained by assessing their relationship with biological markers of aging and dementia. The EPAD v1500.0 data release encompassed core structural scans from 1356 participants 842 fMRI, 831 dMRI, and 858 ASL scans. From 1356 3D T1w images, we identified 17 images with poor quality and 61 with moderate quality. Five QC features - Signal to Noise Ratio (SNR), Contrast to Noise Ratio (CNR), Coefficient of Joint Variation (CJV), Foreground-Background energy Ratio (FBER), and Image Quality Rate (IQR) - were selected as the most informative on image quality by comparison with visual assessment. The multimodal IDPs showed greater impairment in associations with age and dementia biomarkers, demonstrating the potential of the dataset for future clinical analyses

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据